Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 3Terminated 2Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 2Tumor-Agnostic 1Sarcoma 1CNS 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1

Interventions

Rituximab 227Cyclophosphamide 142fludarabine 69Vincristine 66Methotrexate 62Doxorubicin 54fludarabine phosphate 53Lenalidomide 49Etoposide 49Cytarabine 48Prednisone 47Dexamethasone 44Filgrastim 43Bortezomib 38Whole-Body Irradiation 34Gemcitabine 34Melphalan 32Radiotherapy 30ibrutinib 29Granulocyte Colony-Stimulating Factor 29Alemtuzumab 29obinutuzumab 28Tacrolimus 28Mycophenolic Acid 28Antilymphocyte Serum 28venetoclax 27Calcium Dobesilate 27Busulfan 27Bendamustine Hydrochloride 27idelalisib 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Tablets × Lymphoid × Clear all
NCT04554459 2024-08-14

Pona-CELL

Institute of Hematology and Blood Transfusion, Czech Republic

Phase 2 Terminated
4 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00748189 2019-06-25

COMPLEMENT 1

Novartis

Phase 3 Terminated
447 enrolled 32 charts
LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡